Seritage Growth Properties Class A Aktie News

Bragar Eagel & Squire, P.C. Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Seritage (SRG) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder in Seritage  between July 7, 2022 and May 10, 2024 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.

Seritage completed the sale of three properties in Q2 2025, while having contracts for the sale of another three properties. As well, it is in negotiations on another five assets, leaving only seven assets for which it hasn't entered into sales negotiations yet. The faster pace of sales should reduce Seritage's future costs such as interest expenses and development costs.

NEW YORK--(BUSINESS WIRE)--Seritage Growth Properties (NYSE: SRG) (the “Company”), a national owner and developer of retail, residential and mixed-use properties today reported financial and operating results for the three months and six months ended June 30, 2025. "We exercised our option and extended the maturity date of our Term Loan Facility which should allow us to execute sales at appropr...

Bragar Eagel & Squire, P.C. Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Seritage (SRG) To Contact Him Directly To Discuss Their Options

NEW YORK--(BUSINESS WIRE)--Seritage Growth Properties (NYSE: SRG) (the “Company”), a national owner and developer of retail, residential and mixed-use properties, announced that today the Company has made a voluntary prepayment of $40 million toward its $1.6 billion term loan facility provided by Berkshire Hathaway Life Insurance Company of Nebraska (“Berkshire Hathaway”). With the prepayment, ...

NEW YORK--(BUSINESS WIRE)--Seritage Growth Properties (NYSE: SRG) (the “Company”), a national owner and developer of retail, residential and mixed-use properties today reported financial and operating results for the three months ended March 31, 2025. "The Company's strategy following the completion of a smooth CEO transition remains the same. We will continue to pursue our Plan of Sale with th...

The 'Undercovered' Dozen highlights 12 lesser-covered stocks, offering investment opportunities and fostering community discussion on their potential. Abeona Therapeutics is seen as a Buy due to promising FDA approvals for pz-cel and UX111, potentially transforming the company with its first commercial products by 2025. Plains GP Holdings offers stable cash flows and high dividends in the volat...